Vaccination contribute to the development of personal and herd immunity

The present article adduces the evidence in support of the need in the development of personalized vaccines and provides with case studies, substantiating the possibility of the mentioned approach. In order to personalize vaccines one should perform preliminary determination of antibody titers (or delayed-type hypersensitivity skin testing) and the subsequent correction of the immunity in patients with low titers of protective antibodies or hyperimmunization symptoms. Vaccine personalization does not require serious financial expenses. The article provides with the advantages of vaccine personalization and the measures that should be taken to achieve this goal. The difficulties of the personalization and the ways to overcome them are described in the article. Vaccine personalization does not require serious financial expenses. It will contribute to the development of preventive vaccination. Personalization of vaccines is necessary for achieving herd immunity, which leads to the reduction in the incidence of the mentioned infection and usually to the reduction of agent circulation. «Immune domain», which includes mostly recovered and vaccinated patients as well as naturally immuned individuals (by circulating infectious agents), plays a decisive role in the development of herd immunity. The effectiveness of herd immunity is reduced due to genetic variability of an agent, frequent vaccination refusals and rejections. Long-term herd immunity is stipulated by immunological memory.

вакцины, вакцинация, дифференцированный подход, коррекция иммунитета, защитные титры антител, индивидуализация (персонализация) вакцинации, vaccines, vaccination, differentiated approach, correction of immunity, protective antibody titers, vaccination personalization

1. Briko NY. Assessment of the quality and effectiveness of immunization. Available from: http//www.lvrach.ru/2012/10/15435557/ 22/02/2016 (in Russian).

2. Borisevich IV, Movsesyants AA, Gorbunov MA, Medunitsyn NV. Vaccines. Problems and prospects. BIOpreparaty. Profilaktika, diagnostika, lechenie 2010; (3): 8–9 (in Russian).

3. Borisevich IV, Darmov IV, eds. Manual on vaccinoprophylaxis of especially dangerous infections. Kirov; 2011 (in Russian).

4. Dhiman N, Bonilla R, Jacobson R, et al. Differential HLA Gene E expression in Measles Vaccine Seropositive and Seronegative Subjects: A Pilot Study. Scand J Infect Dis. 2003; (35): 332–6.

5. Höhler T, Gerken G, Notghi A, et al. HLA-DRB1*1301 and *1302 protect against chronic hepatitis. B J Hepatol. 1997; 26(3): 503–7.

6. Kaslow RA, Duquesnoy R, Van Raden M, et al. A1, Cw7, B8, DR3 HLA antigen combination associated with rapid decline of T-helper lymphocytes in HIV-1 infection. A report from the Multicenter AIDS Cohort Study. Lancet 1990; 335(8695): 927–30.

7. Khomenko AG, Litvinov VI, Chukanova VP, Pospelov LE. Tuberculosis in patients with various HLA phenotypes. Tubercle 1990; 71(3): 187–92.

8. Zavaglia C, Bortolon C, Ferrioli G, et al. HLA typing in chronic type B, D and C hepatitis. J Hepatol.1996; 24(6): 658–65.

9. Koike S, Taya C, Kurata Ò, et al. Transgenic mice susceptible to polioviruses. Proc Nat Acad Sci USA 1991; (88): 951–5.

10. Ren R, Constantini F, Gorgasz EJ, et al. Transgenic mice expressing a human poliovirus reñeptor: a new model for poliomyelitis. Cell 1990; (63): 353–62.

11. Prilutsky AS, Sohin AA, Maylyan EA. The relationship of intensity of development of antibodies to the causative agents of diphtheria and tetanus with some genetic markers in children vaccinated with DTP. Zhurnal mikrobiologii, epidemiologii i immunobiologii 1994; (2): 89–92 (in Russian).

12. Bothamley GH, Beck JS, Schreuder GM, et al. Association of tuberculosis and M. tuberculosis-specific antibody levels with HLA. J Infect Dis. 1989; 159(3): 549–55.

13. Hayney MS, Poland GA, Jacobson RM, et al. The influence of the HLA DRB1*13 allele on measles vaccine response. J Invest Med. 1996; (44): 261–3.

14. McNeil AJ, Yap PL, Gore SM, et al. Association of HLA types A1-B8-DR3 and B27 with rapid and slow progression of HIV disease. Quarterly Journal of Medicine 1996; 89(3): 177–85.

15. Krasnyansky VP, Potryvaeva NV, Borisevich IV, Gradoboev VN, Pashanina TP, Pshenichnov VA. An evaluation of the possibility of obtaining an inactivated vaccine against Lassa fever. Zhurnal mikrobiologii, epidemiologii i immunobiologii 1994; (6): 74–5 (in Russian).

16. Bondareva TA, Kalininsky VB, Borisevich IV, Bondarev VP, Fomenkov OO. Modern state and prospects for the solution of the problem of the increase the efficacy of emergency prophylaxis and therapy of systemic bacterial infections. Molekulyarnaya meditsina 2009; (5): 21–5 (in Russian).

17. Borisevich IV, Mikhaylov VV, Makhlay AA. Pathogenetic principles of specific prevention and treatment of dangerous viral hemorrhagic fevers. In: Pathogenetic bases of treatment of acute infectious diseases. Collection of scientific works of the 70th anniversary of the birth of Academician V. I. Pokrovsky. Moscow; 1999. P. 236–44 (in Russian).

18. Krasnyansky VP, Potryvaeva NV, Borisevich IV, Gradoboev VN, Pashanina TP, Pshenichnov VA. Experience of preparing inactivated vaccine against Lassa fever. Voprosy virusologii 1993; (6): 276–9 (in Russian).

19. Bogacheva NV, Darmov IV, Borisevich IV, Kryuchkov AV, Pechenkin DV. The time course of changes in cell immunological parameters during administration of live dry plague vaccine. Klinicheskaya laboratornaya diagnostika 2009; (8): 24–6 (in Russian).

20. Georgiev TB. On autovaccinotherapy and the manufacture of autovaccines. Dnepropetrovsk; 1958 (in Russian).

21. Egorova NB, Miroshnichenko IV, Kreynin LS. Immunological reactivity of people at the same time the injected toxoids. In:. Immunological aspects of epidemiology. Kishinev; 1977: 15–6 (in Russian).

22. Popov V. F. Measles and measles vaccine L-16. Moscow: Triada-Õ; 2002 (in Russian).

23. Basova NN, Rusakova GV, Gotvyanskaya TP, et al. The results of serological testing of healthcare workers for the correction of vaccinations against diphtheria. Epidemiologiya i infektsionnye bolezni 1997; (5): 42–6 (in Russian).

24. Ersh AV, Poltavchenko AG, P’yankov SA, et al. The method of estimation of humoral immunity to vaccine-controlled children’s viral infections. Voprosy virusologii 2015; 60(1): 41–5 (in Russian).

25. Medunitsyn NV. Vaccinology. Moscow: Triada-Õ; 2010 (in Russian).

26. Platkov E, Berlin K, Glik Y, Fischbein A. Peculiarities of immune status among hospital employees following vaccination with recombinant DNA Hepatitis  vaccine. Intern Journal on Immunorehabilitation 1999; (12 Suppl): 77.

27. Mironov AN, Supotnitsky MV, Lebedinskaya EV. The phenomenon of antibody-dependent enhancement of infection in vaccinated and convalescents. BIOpreparaty. Profilaktika, diagnostika, lechenie 2013; (3): 12–25 (in Russian).

28. Fulginiti FA, Eller JJ, Downie AW, Kempe CH. Altered reactivity to measles virus. Atypical measles in children previously immunized with inactivated measles virus vaccines. JAMA 1967; 202: 1075–80.

29. Kim HW, Canchola JG, Brandt CD, et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol. 1969; 89: 422–34.

30. Markin VA, Borisevich IV, Makhlay AA. Features of the pathogenesis of viral hemorrhagic especially dangerous fevers. In: Pathogenetic bases of treatment of acute infectious diseases. Collection of scientific works of the 70th anniversary of the birth of Academician V. I. Pokrovsky. Moscow; 1999. P. 228–36 (in Russian).

31. Borisevich IV, Potryvayeva NV, Melnikov SA, Evseev AA, Krasnyansky VP, Maksimov VA. Design of equine serum-based Marburg virus immunoglobulin. Voprosy virusologii 2008; 53(1): 39–41 (in Russian).

32. Mikhaylov VV, Borisevich IV, Timankova GD, Krasnyansky VP, Potryvaeva NV, Lebedinskaya EV, Chernikova NK. Preparation containing immunoglobulin against Ebola fever from horse blood serum and liquid Ebola immunoglobulin. Patent RUS 2130318 05.07.1996 (in Russian).

33. Krasnyansky VP, Mikhaylov VV, Borisevich IV, Potryvaeva NV, Melnikov SA, Timankova GD. Liquid preparation containing immunoglobulin efficient against Marburg fever from horse blood serum (horse immunoglobulin Marburg). Patent RUS 2257916 04.12.2003 (in Russian).

34. Khmelev AL, Borisevich IV, Pantyukhov VB, Pirozhkov AP, Syromyatnikova SI, Shatokhina IV, Melnikov SA, Shagarov EE. Use of guinea pigs to evaluate the efficacy of a heterological immunoglobulin against Bolivian hemorrhagic fever. Voprosy virusologii 2009; 54(4): 42–4 (in Russian).

35. Koza NM, Feldblyum IV, Markovych NI, Parshin AA. Immunological surveillance of diphtheria and measles as a basis of correction of immunity in high-risk groups. In: Immunological reactions in diagnostics, prevention and epidemiological surveillance for infectious diseases. Perm; 1991. P. 66–71 (in Russian).

36. Polland G, Ovsyannikova I, Jacobson R. Identification of an association between HLA class II alleles and low antibody level afner measels immunization. Vaccine 2002; 20: 230–8.

37. Petrov RV, Haitov RM, Pinegin BV, et al. Evaluation of the immune status of the person at mass inspections. Immunologiya 1992; (6): 51–62 (in Russian).

38. Pinegin BV, Cheredeev AN, Haitov RM. Assessment of the human immune system: complexities and achievements. Vestnik RAMN 1999; (5): 1–15 (in Russian).

39. Kolesin ID, Vorobieva AA, Tsibernaya AYu. Model analysis of the effectiveness of early immunization. Epidemiologiya i vaktsinoprofilaktika 2015; (5): 21–6 (in Russian).

40. Ivanchenko OI, Lisitsyna TS, Nikulina NV. Mathematical prediction of the immunological efficacy of revaccination of adults toxoid. In: Immunological reactions in diagnostics, prevention and epidemiological surveillance for infectious diseases. Perm; 1991. P. 71–74 (in Russian).

41. Koshkina NA. The experience of organization of control of serological protection against diphtheria health care workers. In: Modern vaccinology. Perm; 1998. P. 46–7 (in Russian).

42. Organizing and conducting serological monitoring of the state of collective immunity against controllable infections (diphtheria, tetanus, measles, rubella, mumps, polio). Guidelines MU 3.1.1760–03 (in Russian). 43. Kostinov MP. Vaccination of children with allergic diseases. Guidelines. Moscow; 1991 (in Russian).

43. Uchaykin VF, Skachkova LO, Smirnov AV, et al. Vaccination of children with severe somatic pathology. In: Modern vaccinology. Perm; 1998. P. 33–4 (in Russian).

44. Yushkov VV, Yushkova TA. Immunodeficiency and vaccination. In: Modern vaccinology. Perm; 1998. P. 24–5 (in Russian).

45. Hedrich AW. The corrected average attack rate of measles among city children. Am J Epidemiol. 1930; 11(3): 576–600.

46. Briko NI. Assessment of the quality and the effectiveness of vaccination. Meditsinski vestnik 2015; (9): 1–6 (in Russian).

47. Briko NI, Lobzin YuV, Baranov AA, et al. Evaluation of the effectiveness of vaccination: basic approaches and controversial. Pediatricheskaya farmakologiya 2014; 11(4): 8–14 (in Russian).

48. Pokrovsky VI, Pak SG, Briko NI, Danilkin BK. Infectious diseases and epidemiology. Manual for doctors. Moscow: GEOTAR-Media; 2008 (in Russian).

49. Yushchuk ND, Kulagina MG. Flu. In: Infectious Diseases. National guideline. Moscow: GEOTAR-Media; 2009. P. 701–9 (in Russian).

50. Zhdanov VM, Ershov FI. Taming of the Shrew: stories about viruses and virology. Moscow: Meditsina; 1988 (in Russian).

51. Supotnitsky MV. The phenomenon of antigenic imprinting in the epidemic, infectious and post-vaccination processes. BIOpreparaty. Profilaktika, diagnostika, lechenie 2014; (3): 27–40 (in Russian).

52. Medunitsyn NV, Mironov AN, Movsesyants AA. Theory and practice of vaccinology. Moscow: Remedium; 2015 (in Russian).

53. Zverev VV, Semenov BF, Haitov RM. Vaccines and vaccination. National guideline. Moscow: GEOTAR-Media; 2011 (in Russian).

54. Medunitsyn NV. Do people need the vaccines? Moscow: BORGES; 2006 (in Russian).